The G-quadruplex (G4) forming C9orf72 GGGGCC (G4C2) expanded hexanucleotide repeat (EHR)
is the predominant genetic cause of amyotrophic lateral sclerosis
(ALS) and frontotemporal dementia (FTD). Developing selective G4-binding
ligands is challenging due to the conformational polymorphism and
similarity of G4 structures. We identified three first-in-class marine
natural products, chrexanthomycin A (cA), chrexanthomycin
B (cB), and chrexanthomycin C (cC), with
remarkable bioactivities. Thereinto, cA shows the highest
permeability and lowest cytotoxicity to live cells. NMR titration
experiments and in silico analysis demonstrate that cA, cB, and cC selectively bind
to DNA and RNA G4C2 G4s. Notably, cA and cC dramatically reduce G4C2 EHR-caused cell death, diminish G4C2 RNA
foci in (G4C2)29-expressing Neuro2a cells, and significantly
eliminate ROS in HT22 cells. In (G4C2)29-expressing Drosophila, cA and cC significantly
rescue eye degeneration and improve locomotor deficits. Overall, our
findings reveal that cA and cC are potential
therapeutic agents deserving further clinical study.